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Cells express a plethora of interferon-stimulated genes (ISGs) in response to viral infection. Among
these is ISG15, a ubiquitin-like protein (UBL) that can be covalently attached to both host and viral
proteins. Here we review recent advances toward understanding the role and mechanism of ISG15
modification in antiviral defense.Introduction
Secretion of type I interferons (IFNs) from virus-infected cells
is a hallmark of antiviral immunity. Cells that receive these sig-
nals increase expression of interferon-stimulated genes (ISGs),
preparing the cells for impending infection. ISG15, a 15 kDa
ubiquitin-like protein (UBL), has recently emerged as an impor-
tant tool in the struggle against many viral pathogens (reviewed
by Jeon et al., 2010). The ISG15 structure consists of two ubiq-
uitin-likemoieties linked by a short hinge. Like ubiquitin and other
UBLs, ISG15 is attached to target proteins through a C-terminal
Gly-Gly motif. Conjugation of ISG15, commonly referred to as
ISGylation, is a three-step enzymatic cascade (Figure 1A).
The ISG15 E1 enzyme is UBE1L, which specifically activates
ISG15 but not ubiquitin, and the E2 enzyme is UBCH8.
The predominant E3 enzyme appears to be the HECT domain
protein HERC5 because RNA interference against HERC5 abol-
ishes most IFN-induced ISGylation. In addition, coexpression of
UBE1L, UBCH8, HERC5, and ISG15 is sufficient to produce
a level of ISGylation similar to that of IFN stimulation. However,
biochemical evidence that HERC5 directly transfers ISG15 to
substrates is still lacking. Like other UBLs, addition of ISG15 is
reversible; indeed, UBP43 was identified as a deISGylation
enzyme. Notably, expression of UBE1L, UBCH8, HERC5, and
UBP43 is also induced by IFN.
The function of ISG15 since its discovery in the 1980s
remained enigmatic until very recently. Over the past few years,
significant advances have led to a clearer understanding of the
physiological function of ISG15 and several potential antiviral
mechanisms.
Genetic Evidence Linking ISG15 and Antiviral Immunity
The robust induction of ISG15 in response to IFN treatment or
viral infection implies a role for ISG15 in antiviral defense, yet
initial analyses of mice lacking ISG15 or UBE1L revealed no
apparent defect in defense against vesicular stomatitis virus
(VSV) and lymphocytic choriomeningitis virus (LCMV) (Kim
et al., 2006; Osiak et al., 2005). Nevertheless, a growing body
of work strongly suggests a role for ISG15 in defense against
many viral pathogens. ISG15 overexpression in cell culture hasbroad antiviral effects, such as suppressing the replication of
HIV and the budding of Ebola VP40 virus-like particles. Also
consistent with a role for ISG15 in antiviral defense, several
viruses express proteins that antagonize the ISGylation machi-
nery (reviewed by Jeon et al., 2010). Here we focus primarily
on recent results from mouse models of viral infection and the
interaction between the influenza B nonstructural protein 1
(NS1B) and the ISGylation machinery.
Functional Insight from Mouse Models of Viral Infection
Strong evidence that ISG15 protects mammals from viral infec-
tion came from studies using a recombinant chimeric Sindbis
virus system (Lenschow et al., 2005). Exogenous expression of
ISG15 inmice lacking the IFN-a and -b receptors confers protec-
tion against systemic infection and lethality. Importantly, muta-
tion of the two C-terminal glycine residues of ISG15 to alanines
(GG > AA) abrogates this protective effect, suggesting that
ISG15 conjugation is important for protection against Sindbis
virus. In addition, mice lacking ISG15 succumb more readily
than wild-type mice to infection with several viruses, including
Sindbis virus, influenza A and B viruses, herpes simplex virus
type 1 (HSV-1), and murine gammaherpesvirus 68 (gHV68). The
impaired defense against Sindbis virus is rescued in ISG15
knockout mice by expressing wild-type ISG15, but not the GG >
AA mutant (Lenschow et al., 2007). Consistent with a critical role
of ISG15conjugation in antiviral defense,mice lackingUBE1Lare
susceptible to infectionwith Sindbis virus, andmutation of ISG15
Arg151, a residue critical for interaction with UBE1L, abrogates
the protective effect of ISG15 (Giannakopoulos et al., 2009).
UBE1L-deficient mice are also susceptible to infection with influ-
enza B (Lai et al., 2009). Taken together, these results implicate
ISG15 conjugation as a key component of mammalian antiviral
immunity. Interestingly, bone marrow transplantation experi-
ments show that ISG15 exerts its antiviral function exclusively
in cells of nonhematopoetic origin (Lai et al., 2009).
Species Specificity in the ISGylation System
Two reports this year have introduced the intriguing prospect
of species specificity in the ISG15 system, including key differ-
ences between mice and humans (Sridharan et al., 2010; Ver-
steeg et al., 2010). The influenza NS1B protein can antagonizeCell 143, October 15, 2010 ª2010 Elsevier Inc. 187
Figure 1. ISGylation and Its Antiviral Mechanisms
(A) ISG15, like ubiquitin, is attached to substrates in a three-step enzymatic
cascade. In the first step, ISG15 is ‘‘activated’’ by UBE1L in an ATP-dependent
process. ISG15 is then transferred to the E2 UBCH8 and subsequently to
a target protein through the E3 HERC5. Like ubiquitin, ISG15 is conjugated
to a lysine on the target protein through a C-terminal glycine-glycine motif.
(B) Type I interferons (IFNs) induce expression of ISG15 and ISGylation
machinery including HERC5. During infection with influenza A, nonstructural
protein 1 (NS1A) protein is ISGylated on lysine 41. ISGylation inhibits the
binding of NS1A to the nuclear import factor importin-a. Mutation of this lysine
largely protects influenza A from the antiviral actions of type I IFN.
(C) HERC5, likely due to its association with ribosomes, broadly targets newly
synthesized proteins for ISGylation. ISGylation of certain viral proteins,
including those that make up the capsid, could have a dominant-negative
effect by interfering with the precise assembly of higher-order structures.
Thus ISG15 can cause a significant impairment in viral infectivity despite
ISGylation of only a small percentage of the target proteins.host cell ISGylation, one of the earliest indications that the ISGy-
lation system might be antiviral (Yuan and Krug, 2001). Indeed,
NS1B can bind directly to ISG15 (Chang et al., 2008). However,
as mentioned above, ISG15- and UBE1L-deficient mice are
more susceptible to influenza B than their wild-type counter-
parts. This finding suggests that in wild-type mice NS1B fails
to protect the virus from ISGylation. A potential explanation for
this finding has recently been uncovered; NS1B cannot bind to
mouse ISG15. The binding of NS1B to human ISG15 involves
residues within the N terminus and the short hinge region of
ISG15. The five residues in this hinge region are highly conserved
among primates but divergent in other mammalian species
including mouse and dog. Indeed, NS1B can only bind to188 Cell 143, October 15, 2010 ª2010 Elsevier Inc.ISG15 from humans and nonhuman primates. Remarkably,
substitution of residues from the human hinge region with the
corresponding mouse residues abolishes this binding (Sridharan
et al., 2010). Consistent with the species selectivity of the NS1B-
ISG15 interaction, NS1B cannot antagonize mouse ISGylation
(Versteeg et al., 2010). Substitution of the N terminus of mouse
ISG15 with the human N terminus restores the NS1B-ISG15
interaction. This report also reveals that HERC6 is the apparent
E3 protein in mice, whereas mouse HERC5 does not support
ISGylation. These findings warrant careful attention in studies
utilizing mice or mouse cells to study the role, and mechanism
(s) of action, of ISG15. It will be of interest to determine the
extent to which the species specificity of ISG15 and ISGylation
machinery contributes to the different responses among mam-
mals to viral infection.
Biochemical Mechanisms of Antiviral Defense by ISG15
Proteomics studies have identified more than 150 proteins as
putative ISGylation targets, a few of which have been validated
under conditions of endogenous expression (Zhao et al., 2005).
Notably, several of the ISGylation substrates identified are
themselves IFN-induced proteins, such as MxA (myxovirus
resistance A) and RIG-I (which senses viral RNA). However,
even for proteins whose ISGylation can be confirmed, it has
been difficult to determine whether this modification exerts
a functional consequence, in part because only a very small frac-
tion of any cellular protein is modified by ISG15. In principle,
ISGylation could lead to a gain of function, loss of function, or
dominant-negative effect. A gain of function or dominant-nega-
tive effect could allow a small fraction of ISGylated proteins to
exert a strong effect. On the other hand, a loss of function of
a small fraction of proteins is unlikely to have a functional conse-
quence, unless ISGylation occurs preferentially on an ‘‘active’’
pool of proteins. In some cases studied so far, ISGylation
appears to impair the function of target proteins. For example,
ISGylation of filamin B impairs its ability to support IFN-induced
Jun N-terminal kinase (JNK) activity and apoptosis (Jeon et al.,
2009).
There are at least two examples in which ISGylation results in
a gain of function of a cellular target protein. 4EHP binds to the
cap structure of mRNA and inhibits translation by competing
with the translation initiation factor eIF4E. ISGylated 4EHP binds
to the mRNA cap with greater affinity than the unmodified
protein. It has been postulated that ISGylation of 4EHP leads
to selective inhibition of viral RNA translation, which may partly
account for the inhibition of viral protein synthesis by IFN
(Okumura et al., 2007).
A recent study has uncovered a role for ISGylation by HERC5
in the regulation of IRF3, a transcription factor that controls the
production of IFN (Shi et al., 2010). HERC5 interacts with IRF3
and promotes its ISGylation. This ISGylation stabilizes IRF3
by inhibiting its interaction with PIN1, a protein that promotes
IRF3 ubiquitination and degradation. Consistent with a gain-of-
function mechanism, HERC5 promotes expression of IRF3-
dependent genes during viral infection and attenuates replica-
tion of several viruses, including VSV.
In addition to cellular ISGylation targets, recent reports
implicate viral proteins as targets of ISG15 modification. These
studies provide fresh insights into the antiviral mechanisms of
ISG15.
Specific Targeting of Influenza A NS1 Protein
To determine whether targeting of any viral proteins is involved in
ISG15-mediated impairment of influenza A replication, Krug and
colleagues coexpressed influenza A proteins with the ISGylation
machinery and found that the NS1 protein of the H3N2 influenza
A/Udorn/72 (Ud) virus is an ISG15 substrate (Zhao et al., 2010).
ISGylation of NS1A could also be observed following infection
of IFN-b-treated cells with Ud virus. Moreover, NS1A binds
specifically to HERC5 but not the closely related HERC4 and
HERC6. Similarly, Wang and colleagues find that NS1A interacts
with HERC5, and that HERC5 promotes its ISGylation (Tang
et al., 2010). NS1A is a virulence factor that can inhibit host cell
pre-mRNA processing and the IFN-induced 20 to 50 oligo(A)
synthetase/RNase L pathway. Importantly, both groups find
evidence that ISGylation of NS1A impairs influenza replication,
although different conclusions were reached regarding the
mechanism(s) of this impairment.
Through a combination of affinity purification, mass spectrom-
etry, and mutagenesis, Krug and colleagues find that NS1A
Lys41 appears to be themajor ISG15 acceptor site. As this lysine
lies within the region of NS1A responsible for binding to double-
stranded RNA and the nuclear import factor importin-a, the
authors assayed the ability of ISGylation to affect either of these
interactions. Whereas ISGylated NS1A binds as well as non-
ISGylated NS1A to polyI:C, it fails to interact with importin-a,
suggesting that ISGylation of NS1A causes a specific loss of
function. Importantly, K41R mutation significantly enhances
the ability of the virus to replicate in the presence of IFN-b, sug-
gesting that specific targeting of NS1A protein by ISG15 impairs
influenza A replication through a loss-of-function mechanism
(Figure 1B).
By contrast, mutagenesis results from Wang and colleagues
indicate that ISGylation of multiple lysines on NS1A contributes
to the impairment of viral replication. Moreover, ISGylation of
NS1A appears to cause a severe impairment in the binding to
U6 snRNA and dsRNA. In addition, ISGylation also impairs
self-interaction of NS1A.
The reasons for the discrepancies regarding NS1A’s ISGyla-
tion site(s) and the ability of ISGylated NS1A to bind to RNA
are unclear. It is noteworthy that the influenza viruses used by
the two groups differ in origin, so their interactions with the
host cell may be different. In any case, these reports identify
the first viral ISG15 target and suggest that ISGylation of this
target impairs viral replication through a loss-of-function mech-
anism. It is at present not clear how ISGylation of a small
percentage of NS1A leads to such a dramatic impairment in viral
replication.
Broad Targeting of Newly Synthesized Viral Proteins
A recent article inMolecular Cell suggests an intriguing model for
understanding the antiviral activity of ISG15 (Durfee et al., 2010).
Only a minority of constitutively expressed proteins from the
aforementioned proteomics study can be confirmed as ISGyla-
tion substrates at their endogenous levels, even when ISG15
and the ISGylation enzymes are overexpressed. By contrast,
most of these proteins are confirmed as ISGylation substrates
when they are exogenously expressed along with the ISGylationmachinery. In fact, most (but not all) exogenously expressed
proteins, including bacterial proteins and the TAP affinity tag,
are also ISGylated using this method. These results raise doubts
regarding the physiological significance of putative ISGylation
substrates.
Yet Huibregtse and colleagues embraced what could easily
have been dismissed as a technical artifact. Their subsequent
results suggest that a key variable determining whether or not
a protein gets ISGylated is its new synthesis in the presence of
ISG15 and ISGylationmachinery. Proteins that are newly synthe-
sized, for instance those that are expressed from a transfected
plasmid, in the presence of the ISGylation machinery are readily
ISGylated. Moreover, multiple fragments of a protein that are
expressed as deletion mutants appear equally susceptible to
ISGylation, suggesting a lack of rigid specificity determinants
within the protein structure as might have been presumed.
A potential explanation of these results is that newly synthesized
proteins are targets for ISGylation; indeed, fractionation of cyto-
solic extracts reveals that HERC5 is associated with ribosomes.
Thus the authors propose that HERC5 broadly, and at least
somewhat nonspecifically, targets newly synthesized proteins
for ISGylation (Figure 1C).
This idea implies that some viral proteins will be ISGylated
during replication. As some viral structural proteins, such as
those that make up the capsid, must precisely assemble into
higher-order structures, it is possible that ISGylation of a small
fraction of these proteins could have a dominant-negative effect.
Indeed, using the human papillomavirus (HPV) pseudovirus
system, in which the HPV L1 and L2 capsid proteins are able
to package a plasmid expressing green fluorescent protein
and deliver it to new cells, the authors show that ISGylation of
approximately 10% of L1 protein is associated with a 70%
decrease in infectivity. The mechanistic basis of the infectivity
impairment by ISG15 remains to be determined; perhaps entry
of the virus into new cells or release of the nucleic acids into
the infected cells is impaired. In any case, the results suggest
that ISG15 can indeed cause a dominant-negative impairment
of viral protein function, an appealing idea that might explain
how ISGylation of a small fraction of a given protein can have
potent antiviral effects. In addition, as postulated by the authors
of this report, these findings suggest that ISGylation of some,
perhaps most, host proteins could be a by-product of the cell’s
effort to maximize ISGylation of viral proteins.
Perspectives
Although ISG15 is the first UBL known to exist, its biological role
and mechanism of action are less well understood than those of
most of the other UBLs, such as SUMO or NEDD8. This is in part
due to the absence of homologs of ISG15 and its conjugation
machinery (e.g, UBE1L) in experimental organisms such as
yeast, Drosophila, or C. elegans. Nevertheless, significant prog-
ress has been made in the past few years in the identification of
the enzymatic machinery that carries out ISGylation and in the
elucidation of the role of ISGylation in antiviral defense. The
recent findings of the direct antiviral activity of ISG15 through
both specific and broad modification of viral proteins represent
a major advance in understanding the antiviral mechanisms of
ISGylation. Some ISGylated host proteins also appear toCell 143, October 15, 2010 ª2010 Elsevier Inc. 189
mediate its antiviral effects (for example, ISGylated 4EHP and
IRF3 as mentioned above).
Although upregulating the expression of ISGylation machinery
is a primary means of regulating ISGylation, additional regulatory
mechanisms clearly exist, for example, NS1B’s binding to ISG15
and HERC50s association with ribosomes and specific sub-
strates like NS1A. Biochemical reconstitution of the ISGylation
processwould potentially facilitate the identification of additional
factors that regulate ISGylation.
An emerging theme from the recent mechanistic studies is that
ISGylation alters a protein’s ability to engage in its typical inter-
actions (such as with other proteins or RNA). The basis for this
alteration is as yet unclear. It is likely that the presence of
ISG15 could directly interfere with the normal protein-protein
or protein-RNA interface. It is also feasible that ISGylation could
induce allosteric changes in protein structure, or that ISG15-
binding protein(s) may be present in cells and could modulate
interactions between ISGylated proteins and their typical
partners.
It is noteworthy that mice lacking ISG15 are not as susceptible
to viral infection as IFN receptor knockout mice, indicating
that ISGylation contributes to, but is not solely responsible
for, the antiviral effects of IFN in mice (Lenschow et al., 2007).
Recent work demonstrating marked differences in the interac-
tion between influenza B virus and the ISGylation machinery of
mice and humans suggests that ISG15 might play a more prom-
inent antiviral role in human. Indeed, blocking ISGylation in
human cells severely impairs IFN-induced antiviral activity
against influenza A virus (Hsiang et al., 2009). Future research
could also reveal other functions of ISGylation unrelated to its
antiviral effect. Indeed, the levels of ISG15 and its conjugation
to cellular proteins are elevated in several tumors and tumor-
derived cell lines (Desai et al., 2006).
Understanding the roles and mechanism of action of ISGs,
such as ISG15, in antiviral defense may pave the way to more
effective antiviral therapies. For example, viral proteins that
counter the IFN response by antagonizing ISGylation might
make appealing therapeutic targets.
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